Phase I Trial of 5,6 Dimethylxanthenone - 4 - Acetic Acid (DMXAA) in Solid Tumors
This is a dose escalation study conducted at a single center in New Zealand. Patients
received dimethylxanthenone acetic acid (DMXAA) IV over 20 minutes once every three weeks,
up to a maximum of 12 courses.
Cohorts of 3 patients received escalated doses of DMXAA until the maximum tolerated dose
(MTD) was determined. The MTD is defined as the dose preceding that at which 2 of 3 patients
experience dose limiting toxicity.
Patients had solid tumors for which there was no standard therapy or were refractory to
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Toxicity of DMXAA
Dr Paul Thompson
New Zealand: Health Research Council